New nanopharmaceutical may help overcome resistance to specific anticancer drugs
Conclusions: Results generated through this translational research plan suggest that CRLX101 can overcome HIF-1α-mediated acquired resistance to antiangiogenic drugs, assisting the use of CRLX101 in combination with antiangiogenic medicines as an exciting new paradigm for the treatment of cancer.
Related Posts:Cleveland Clinic’s preventive breast cancer vaccine…Harvard Stem Cell Institute publishes initial clinical trialImportant advance in the fight against skin cancerNew IBS treatment shows possible in Phase 2 researchNew blood test could help millions of patients with…The post New nanopharmaceutical may help overcome resistance to specific anticancer drugs appeared first on My Irritable Bowel Syndrome Story.
Source: My Irritable Bowel Syndrome Story - Category: Other Conditions Authors: Ken Tags: IBS News Source Type: blogs
More News: Avastin | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Chemistry | Chemotherapy | Clinical Trials | Conferences | Epithelial Cancer | Gastric (Stomach) Cancer | Gastroenterology | Harvard | Hospital Management | Irritable Bowel Syndrome | Kidney Cancer | Lung Cancer | Melanoma | Men | Nanotechnology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Nutrition | Ovarian Cancer | Ovaries | Pharmaceuticals | Radiation Therapy | Renal Cell Carcinoma | Skin | Skin Cancer | Stem Cell Therapy | Stem Cells | Toxicology | Urology & Nephrology | Vaccines | Xeloda